The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Researchers are examining why insurance plans frequently restrict access to GLP-1 medications like Ozempic and Wegovy despite their proven health benefits. The study highlights that while these drugs are cost-effective, their high price and the massive number of eligible patients create a significant budget impact for insurers.
Why it matters
The tension between clinical cost-effectiveness and insurance budget sustainability directly impacts patient access to life-changing obesity and diabetes treatments.
GLP-1 medications have been shown to improve health and offer strong value for their price, yet many insurance plans continue to restrict access. Researchers at the University of Mississippi are investigating the financial and practical reasons behind those limits, along with the consequences for patients.
A recent analysis from the Institute for Clinical and Economic Review, an independent nonprofit that assesses the value of medical treatments, concluded that GLP-1 drugs including Ozempic, Wegovy and Zepbound are cost-effective. In other words, the health improvements they provide are considered substantial enough to justify their price.
Why Cost-Effective Does Not Mean Affordable
In a study published in the Journal of Managed Care and Specialty Pharmacy , Sujith Ramachandran, associate professor of pharmacy administration, explained that a treatment can be cost-effective without being cost-saving for insurers.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in